Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, randomized, double-blind, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetic profile of vesicular monoamine transporter 2 (VMAT2) inhibitor in healthy participants

Trial Profile

A phase I, randomized, double-blind, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetic profile of vesicular monoamine transporter 2 (VMAT2) inhibitor in healthy participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs Neuropsychotherapeutics (Primary)
  • Indications Neurological disorders; Psychiatric disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Feb 2019 According to a Neurocrine Biosciences media release, the multiple dosing portion of the study is ongoing and is expected to be completed during the first half of 2019.
    • 16 Nov 2018 New trial record
    • 05 Nov 2018 According to a Neurocrine Biosciences media release, the study s anticipated to be completed during the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top